



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_596_25

You asked:

I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions.

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

95 at Cwm Taf Morgannwg University Health Board (CTMUHB).

CTMUHB refer patients to the [University Hospital of Wales](#) (Cardiff and Vale University Health Board) for AST, inpatient intensive SACT, CAR-T, initiation of BiTE therapies and clinical trials.

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

- **Belantamab Mafodotin [Blenrep] = 0**
- **Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone = 0**
- **Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone = 0**
- **Bortezomib [Velcade] ± Dexamethasone = ****
- **Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) = 0**
- **Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) = 0**
- **Carfilzomib [Kyprolis] + Dexamethasone = 0**
- **Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) = ****
- **Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) = 25**
- **Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) = 12**
- **Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) = 18**
- **Daratumumab [Darzalex] monotherapy = 0**
- **Elranatamab = ****
- **Idecabtagene vicleucel [Abecma] = 0**
- **Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) = ****
- **Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) = ****
- **Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) = 16**

- **Lenalidomide [Revlimid] + Dexamethasone = 8**
- **Lenalidomide [Revlimid] monotherapy = 17 (as maintenance post-SCT)**
- **Panobinostat + Bortezomib + Dexamethasone = 0**
- **Pomalidomide [Imnovid] + Dexamethasone = ****
- **Selinexor + Bortezomib [Velcade] + Dexamethasone = 0**
- **Selinexor + Dexamethasone = 0**
- **Talquetamab = 0**
- **Teclistamab [Tecvayli] = 0**
- **Any other systemic anti-cancer therapy [please specify]**
Cyclophosphamide + Dexamethasone = **
Melphalan + Prednisolone + Thalidomide = **

Q3. In the last 6 months, how many patients have been initiated* on the following regimens?

- **Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) = 0**
- **Carfilzomib [Kyprolis] + Dexamethasone = 0**
- **Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) = ****
- **Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) = ****
- **Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd) = 0**
- **Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) = ****
- **Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) = ****
- **Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) = ****
- **Lenalidomide [Revlimid] monotherapy = ** (as maintenance post-SCT)**
- **Lenalidomide [Revlimid] + Dexamethasone = ****
- **Selinexor + Bortezomib [Velcade] + Dexamethasone = 0**
- **Selinexor + Dexamethasone = 0**
- **Any other systemic anti-cancer therapy [please specify]**
Cyclophosphamide + Dexamethasone = **
Melphalan + Prednisolone + Thalidomide = **

****Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation.***

Q4. In the last 6 months, how many patients have received the following second-line treatment?

- **Lenalidomide [Revlimid] + Dexamethasone = ****

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with

other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.